SCHEMBL4732176

SCHEMBL4732176

O=C(O)N(CO)c1ccccc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.54
GLA P06280 2/20 0.54
TSHR P16473 2/20 0.54
HTT P42858 4/20 0.50
SMN1; SMN2 Q16637 3/20 0.50
NPC1 O15118 2/20 0.50
RAB9A P51151 2/20 0.50
PAX8 Q06710 1/20 0.50
KMT2A Q03164 3/20 0.48
MEN1 O00255 2/20 0.48
CYP3A4 P08684 1/20 0.48
CYP2C9 P11712 1/20 0.48
CYP2C19 P33261 1/20 0.48
TP53 P04637 1/20 0.47
NPSR1 Q6W5P4 2/20 0.46
GAA P10253 1/20 0.45
TRPM8 Q7Z2W7 1/20 0.44
LTB4R2 Q9NPC1 1/20 0.44
POLB P06746 1/20 0.43
ADRA2C P18825 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL547256 0.84 ALDH1A1 (0.52) ALDH1A1GLATSHRHTTSMN1; SMN2
SCHEMBL9160381 0.83 ALDH1A1 (0.56) ALDH1A1GLATSHRHTTSMN1; SMN2
SCHEMBL7505138 0.82 ALDH1A1 (0.55) ALDH1A1GLATSHRHTTSMN1; SMN2
SCHEMBL7791465 0.82 HDAC3 (0.51) ALDH1A1GLATSHRHTTSMN1; SMN2
SCHEMBL28647892 0.82 ALDH1A1 (0.50) ALDH1A1GLATSHRHTTSMN1; SMN2
SCHEMBL7919582 0.80 ALDH1A1 (0.53) ALDH1A1GLATSHRHTTSMN1; SMN2
SCHEMBL11287043 0.79 ALDH1A1 (0.58) ALDH1A1GLATSHRHTTSMN1; SMN2
SCHEMBL1927016 0.79 ALDH1A1 (0.69) ALDH1A1GLATSHRHTTSMN1; SMN2
SCHEMBL380050 0.79 ALDH1A1 (0.76) ALDH1A1GLATSHRHTTSMN1; SMN2
SCHEMBL13735234 0.79 ALDH1A1 (0.52) ALDH1A1GLATSHRHTTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250229248-A1 CONTINUOUS-FLOW PREPARATION METHOD OF AMINO ALCOHOL COMPOUNDS UNIV FUDAN (CN) 2025-07-17 US disclosed
CN-118420478-A Continuous flow preparation method of amino alcohol compound 复旦大学 2024-08-02 CN disclosed
CN-101535303-B Heterocyclic compounds suitable for the treatment of diseases related to elevated lipid level NOVARTIS AG 2012-07-18 CN disclosed
CN-101535303-A Heterocyclic compounds suitable for the treatment of diseases related to elevated lipid level NOVARTIS AG (CH) 2009-09-16 CN disclosed
WO-2008053479-A1 SELF-IMMOLATIVE POLYMERS RAMOT AT TEL AVIV UNIVERSITY LTD. (IL) 2008-05-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250229248-A1 CONTINUOUS-FLOW PREPARATION METHOD OF AMINO ALCOHOL COMPOUNDS BCAT2, ADH1C, BCAT1 ALDH1A1 80/4885GLA 4863/4885TSHR 1950/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.